372 related articles for article (PubMed ID: 7889015)
1. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
Weaver CH; Bensinger WI; Appelbaum FR; Lilleby K; Sandmaier B; Brunvand M; Rowley S; Petersdorf S; Rivkin S; Gooley T
Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015
[TBL] [Abstract][Full Text] [Related]
2. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
Demirer T; Ilhan O; Mandel NM; Arat M; Günel N; Celebi H; Ustün C; Akan H; Demirer S; Aydintuğ S; Uysal A; Koç H
Bone Marrow Transplant; 2000 Apr; 25(7):697-703. PubMed ID: 10745253
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease.
Schiffman KS; Bensinger WI; Appelbaum FR; Rowley S; Lilleby K; Clift RA; Weaver CH; Demirer T; Sanders JE; Petersdorf S; Gooley T; Weiden P; Zuckerman N; Montgomery P; Maziarz R; Klarnet JP; Rivkin S; Trueblood K; Storb R; Holmberg L; Buckner CD
Bone Marrow Transplant; 1996 Jun; 17(6):943-50. PubMed ID: 8807098
[TBL] [Abstract][Full Text] [Related]
4. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
[TBL] [Abstract][Full Text] [Related]
6. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors.
Hara J; Osugi Y; Ohta H; Matsuda Y; Nakanishi K; Takai K; Fujisaki H; Tokimasa S; Fukuzawa M; Okada A; Okada S
Bone Marrow Transplant; 1998 Jul; 22(1):7-12. PubMed ID: 9678789
[TBL] [Abstract][Full Text] [Related]
7. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
8. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
[TBL] [Abstract][Full Text] [Related]
9. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
[TBL] [Abstract][Full Text] [Related]
10. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation.
Demirer T; Uysal VA; Ayli M; Genc Y; Ilhan O; Koc H; Dagli M; Arat M; Gunel N; Fen T; Dincer S; Ustael N; Yildiz M; Ustun T; Seyrek E; Ozet G; Muftuoglu O; Akan H
Bone Marrow Transplant; 2003 May; 31(9):755-61. PubMed ID: 12732881
[TBL] [Abstract][Full Text] [Related]
11. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer.
Holmberg LA; Demirer T; Rowley S; Buckner CD; Goodman G; Maziarz R; Klarnet J; Zuckerman N; Harrer G; McCloskey R; Gersh R; Goldberg R; Nichols W; Jacobs A; Weiden P; Montgomery P; Rivkin S; Appelbaum FR; Bensinger WI
Bone Marrow Transplant; 1998 Oct; 22(7):651-9. PubMed ID: 9818692
[TBL] [Abstract][Full Text] [Related]
12. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
[TBL] [Abstract][Full Text] [Related]
13. [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means].
Sola Rocabert C; Mesía R; Mendoza L; Tabernero JM; Amill B; Maroto P; Bellet M; Ojeda B; Alonso MC; Verger G
Med Clin (Barc); 1995 Oct; 105(11):407-11. PubMed ID: 7475451
[TBL] [Abstract][Full Text] [Related]
14. High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study.
Kalifa C; Hartmann O; Demeocq F; Vassal G; Couanet D; Terrier-Lacombe MJ; Valteau D; Brugieres L; Lemerle J
Bone Marrow Transplant; 1992 Apr; 9(4):227-33. PubMed ID: 1534708
[TBL] [Abstract][Full Text] [Related]
15. High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer.
Gutierrez-Delgado F; Holmberg LA; Hooper H; Appelbaum FR; Livingston RB; Maziarz RT; Weiden P; Rivkin S; Montgomery P; Kawahara K; Bensinger W
Bone Marrow Transplant; 2000 Jul; 26(1):51-9. PubMed ID: 10918405
[TBL] [Abstract][Full Text] [Related]
16. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation for metastatic breast cancer: immunologic consequences affecting clinical outcome.
Chakraborty N; Bilgrami S; Maness L; Guo C; Perez-Diez A; Mukherji B; Tutschka P
Bone Marrow Transplant; 1999 Oct; 24(8):837-43. PubMed ID: 10516693
[TBL] [Abstract][Full Text] [Related]
17. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
18. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
Demirer T; Ayli M; Fen T; Ozcan M; Arat M; Buyukberber S; Arslan O; Gurman G; Akan H; Ilhan O
Bone Marrow Transplant; 2004 Nov; 34(9):781-6. PubMed ID: 15354206
[TBL] [Abstract][Full Text] [Related]
19. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
Shimoni A; Smith TL; Aleman A; Weber D; Dimopoulos M; Anderlini P; Andersson B; Claxton D; Ueno NT; Khouri I; Donato M; Korbling M; Alexanian R; Champlin R; Giralt S
Bone Marrow Transplant; 2001 Apr; 27(8):821-8. PubMed ID: 11477439
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.
deMagalhaes-Silverman M; Bloom E; Lembersky B; Lister J; Pincus S; Rybka W; Voloshin M; Wilson J; Ball E
Clin Cancer Res; 1997 Feb; 3(2):193-7. PubMed ID: 9815672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
